Evidence map›Paper›PMID 39867052›Full record

ArticleCureus2024

Progressive Familial Intrahepatic Cholestasis Type 2 in an Infant: Diagnostic Challenges and Multidisciplinary Management.

Najeeb Ullah, Somaan Anthony, Arzoo Siddiqi, Nimra Akram, Bismil Afghan

RetractedAbstract readCase ReportsRetracted Publication
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Najeeb UllahInternal Medicine, Rehman Medical Institute, Peshawar, PAK.
Somaan AnthonyInternal Medicine, Lady Reading Hospital, Peshawar, PAK.
Arzoo SiddiqiInternal Medicine, Dow University of Health Sciences, Karachi, PAK.
Nimra AkramInternal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
Bismil AfghanInternal Medicine, Nishtar Medical University, Multan, PAK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare genetic disorder characterized by severe intrahepatic cholestasis, which often manifests in infancy with progressive liver dysfunction. We present the case of a 3-month-old infant with a one-month history of jaundice, vomiting, and bloody stools, presenting a unique set of diagnostic challenges. Initial clinical and laboratory findings indicated significant liver dysfunction, prompting further imaging and genetic analysis. An abdominal ultrasound revealed hepatomegaly with a coarse liver texture, while a hepatobiliary iminodiacetic acid (HIDA) scan ruled out biliary atresia. Ultimately, genetic testing confirmed a mutation in the ABCB11 gene, diagnostic of PFIC2. Management included total parenteral nutrition to support growth, ursodeoxycholic acid to improve bile flow, and rifampicin to alleviate pruritus. Due to the severity of the disease, a liver transplant is planned as the definitive treatment following stabilization through supportive care. This case underscores the importance of a high index of suspicion, timely genetic testing, and a multidisciplinary approach in managing PFIC2 to optimize patient outcomes.

Indexed as

abcb11 mutationcholestasisliver transplantationpediatric liver diseasepfic2progressive familial intrahepatic cholestasis

Identifiers

PMID39867052
PMCPMC11762005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.